Abstract

AMP-activated protein kinase (AMPK), a critical sensor of energy sufficiency, acts as central metabolic switch in cell metabolism. Once activated by low energy status, AMPK phosphorylates key regulatory substrates and turns off anabolic biosynthetic pathways. In contrast, the mammalian/mechanistic target of rapamycin (mTOR) is active when there are sufficient nutrients for anabolic reactions. A critical factor regulating mTOR is phosphatidic acid (PA), a central metabolite of membrane lipid biosynthesis and the product of the phospholipase D (PLD)-catalyzed hydrolysis of phosphatidylcholine. PLD is a downstream target of the GTPase Rheb, which is turned off in response to AMPK via the tuberous sclerosis complex. Although many studies have linked AMPK with mTOR, very little is known about the connection between AMPK and PLD. In this report, we provide evidence for reciprocal regulation of PLD by AMPK and regulation of AMPK by PLD and PA. Suppression of AMPK activity led to an increase in PLD activity, and conversely, activation of AMPK suppressed PLD activity. Suppression of PLD activity resulted in elevated AMPK activity. Exogenously supplied PA abolished the inhibitory effects of elevated AMPK activity on mTOR signaling. In contrast, exogenously supplied PA could not overcome the effect AMPK activation if either mTOR or Raptor was suppressed, indicating that the inhibitory effects of PLD and PA on AMPK activity are mediated by mTOR. These data suggest a reciprocal feedback mechanism involving AMPK and the PLD/mTOR signaling node in cancer cells with therapeutic implications.

Highlights

  • AMPK, which monitors cellular energy levels, is dysregulated in most cancers

  • Activation of AMPK Suppresses phospholipase D (PLD) Activity—To investigate a connection between PLD and AMPK activities, we examined the effect of glucose deprivation, which is known to elevate AMPK activity, on PLD activity

  • An emerging theme in cancer is that these signaling nodes are dysregulated, with AMPK being suppressed and mechanistic target of rapamycin (mTOR) being activated during tumorigenesis [33]

Read more

Summary

Background

AMPK, which monitors cellular energy levels, is dysregulated in most cancers. Results: AMPK suppresses PLD activity, and PLD suppresses AMPK via mTOR. Exogenously supplied PA could not overcome the effect AMPK activation if either mTOR or Raptor was suppressed, indicating that the inhibitory effects of PLD and PA on AMPK activity are mediated by mTOR. These data suggest a reciprocal feedback mechanism involving AMPK and the PLD/mTOR signaling node in cancer cells with therapeutic implications. PLD mTOR complex; TSC, tuberous sclerosis complex; GAP, GTPase-activating protein; Rheb, Ras homolog enriched in brain; PLD, phospholipase D; PA, phosphatidic acid; TPA, 12-O-tetradecanoylphorbol-13-acetate; 4E-BP, eIF4E-binding protein; ACC, acetyl-CoA carboxylase; ULK, UNC-51-like kinase; AICAR, 5-aminoimidazole-4-carboxamide-1-␤-D-ribofuranoside; PS, phosphatidylserine. This study reveals a means for cancer cells to suppress AMPK to promote cell proliferation

EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call